This Practice Point commentary discusses the study by Denzinger et al. in which patients with high-grade T1 (HGT1) bladder cancer were treated by transurethral resection with either white-light ...

Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...

In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...

Please provide your email address to receive an email when new articles are posted on . Transurethral resection of bladder tumor plus systemic therapy induced clinical complete response among a large ...

Accurate documentation of lesions during transurethral resection of bladder tumors (TURBT) is essential for precise diagnosis, treatment planning, and follow-up care. However, optimizing schematic ...

The guidelines state that clinicians should offer blue light cystoscopy, if available, as an adjunct to traditional white light cystoscopy (WLC) to increase tumor detection and decrease recurrence.

The performance of TURBT with PDD is not substantially different from a TURBT under conventional white-light. It is rather a supplement, namely the preinterventional administration of the substance ...

Most superficial bladder tumors are treated with transurethral resection (TUR) followed by chemotherapy, but recent studies suggest that performing a second TUR can improve prognosis by detecting ...

Background: A 59-year-old female presented with a history of recurrent superficial bladder cancer. Since the initial diagnosis 12 years earlier, she had had 12 recurrences, all treated with ...

Computer-Assisted Flagging of Individuals at High Risk of Colorectal Cancer in a Large Health Maintenance Organization Using the ColonFlag Test Patients undergoing TURBT were retrospectively ...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ Endoscopy-America, Inc., announces the commercial launch of the PDD Blue Light Flexible Video Cystoscopy System for enhanced detection of non-muscle ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate ...